PD-1-PD-L1

PD-1/PD-L1-IN-34 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 0.029 μM, and demonstrates a binding affinity towards PD-L1 with a KD of 0.1554 μM. This compound activates the immune microenvironment, showcasing significant anti-tumor activity which reinforces its potential in cancer immunotherapy research. PD-1/PD-L1-IN-34 is an invaluable tool for elucidating mechanisms of immune modulation and evaluating therapeutic strategies in oncology.

PD-1/PD-L1-IN-28 is a potent inhibitor of the PD-1/PD-L1 signaling pathway, exhibiting an IC50 value of 0.744 µM. This compound demonstrates significant potential in the modulation of tumor immunity, making it a valuable reagent for cancer immunotherapy research. Its ability to disrupt immune checkpoint interactions positions PD-1/PD-L1-IN-28 as an important tool for studying immune responses in various tumor models.

CYP51/PD-L1-IN-4 is a potent dual-target inhibitor of CYP51 and PD-L1, demonstrating IC50 values of 0.17 μM and 0.021 μM, respectively. This compound exhibits significant antifungal activity and is effective against drug-resistant fungal strains in vitro. CYP51/PD-L1-IN-4 is suitable for research applications focused on fungal infections and the interplay between fungal pathogens and immune checkpoint regulation.

PD-1/PD-L1-IN-22 is a small-molecule inhibitor specifically targeting the PD-1/PD-L1 protein-protein interaction. With an IC50 value of 0.732 μM, it effectively disrupts this pathway, making it a valuable tool in cancer, infectious disease, and autoimmune disease research. Its ability to modulate immune responses positions PD-1/PD-L1-IN-22 as a significant compound for therapeutic development in immunooncology and related fields.

PD-1/PD-L1-IN-18 is a small-molecule inhibitor that specifically targets the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 of 1.054 μM. This compound effectively blocks PD-1/PD-L1 signaling, facilitating enhanced T-cell activation and antitumor responses. It is valuable for research applications focused on immunotherapy and cancer treatment strategies.

PD-L1-IN-8 is a selective PD-L1 inhibitor with an IC50 of 0.89 nM. It demonstrates low inhibition of cytochrome P450 enzymes and minimal hERG activity, indicating a favorable safety profile. This compound is specifically useful in the investigation of PD-L1 mediated immune evasion in colon cancer research, contributing to the understanding of tumor-immune system interactions.

PD-1/PD-L1-IN-25 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 16.17 nM. This compound effectively enhances T cell antitumor immunity in peripheral blood mononuclear cells (PBMCs). PD-1/PD-L1-IN-25 is instrumental for cancer research, particularly in studies focused on immunotherapy and tumor microenvironment modulation.

PD-L1/CD-73-IN-1 is a potent inhibitor of PD-L1 and CD73, exhibiting IC50 values of 6 nM and 0.773 μM, respectively. This compound demonstrates significant biological activity by inhibiting tumor cell growth both in vitro and in vivo. It is an essential tool for research applications focused on immune modulation and cancer therapy.

PD-1/PD-L1-IN-58 is a selective inhibitor of the PD-1/PD-L1 pathway, demonstrating a dissociation constant (KD) of 77.60 nM for PD-L1 in comparison to PD-1. This compound exhibits oral bioactivity and is particularly relevant for investigations into immune modulation and potential therapeutic strategies against influenza A virus. Its mechanism of action makes it a valuable tool for research aimed at understanding and manipulating immune responses in various disease contexts.

LH1306 is a C2-symmetric inhibitor specifically targeting the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 value of 25 nM. This compound is pivotal for studies investigating immune checkpoint blockade and its potential applications in anti-tumor research. By modulating immune responses, LH1306 serves as a valuable tool for exploring therapeutic strategies in cancer immunotherapy.

Nilvanstomig is an anti-PD-1/TIGIT antibody that targets the PD-1/TIGIT pathway, thereby facilitating T cell activation and enhancing natural killer (NK) cell anti-tumor activity. This compound is particularly relevant in the study of advanced cervical cancer and contributes to research focused on immune modulation and cancer immunotherapy. Its mechanism of action underscores its potential for strengthening anti-tumor responses in various oncological contexts.

Davoceticept is a fusion protein consisting of the CD80 (1-107) fragment linked to IGHG1 Fc via a peptidyl linker, targeting CTLA-4 and PD-L1. This variant CD80 vIgD-Fc acts as an immune checkpoint inhibitor, enhancing T cell activation and promoting anti-tumor responses. Its applications include cancer immunotherapy and studying immune modulation in various malignancies, making it a valuable tool for researchers investigating therapeutic strategies in cancer treatment.